The Multidisciplinary Association for Psychedelic Studies, a nonprofit leader in the pharmaceutical psychedelics industry, has raised more than $100 million in a Series A private stock sale.  

MAPS needed the money to fund the final stages of its application for regulatory approval to sell MDMA, also known as Ecstasy, to treat post-traumatic stress disorder, the organization said in an announcement Friday.